Clinical development failure or delay
The company has no approved products and depends on successful advancement of pipeline assets.
- Scope
- FHD-909 and other Lilly-partnered programs
- Materiality
- high
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company built around its proprietary Gene Traffic Control platform, which is used to discover and develop medicines that modulate chromatin regulatory systems. The company’s lead efforts are centered on oncology programs, including the SMARCA2-selective inhibitor FHD-909, and it increasingly operates through a major strategic collaboration with Lilly rather than through internal product sales.
−268,7 %
−240,3 %
+36,8 %
2.73
2.73
| % | |
|---|---|
| Platform discovery technology | 20% Proprietary Gene Traffic Control platform used to identify and optimize drug candidates against chromatin-regulatory targets. |
| Lead oncology program | 25% SMARCA2-selective inhibitor program, including FHD-909, aimed at oncology applications. |
| Partnered oncology programs | 25% Additional Lilly-partnered oncology target program and shared development assets. |
| Discovery collaborations | 20% Three discovery programs where Lilly leads later-stage development and Foghorn retains economics. |
| Collaboration revenue and economics | 10% Upfront, milestone, royalty, and profit-share economics generated from strategic partnerships. |
Foghorn does not sell approved medicines to end patients; its primary commercial counterparties are large...
- Strategic pharma collaboratorprimary
Large pharmaceutical companies that license or co-develop platform-derived oncology programs and pay upfronts, milestones, royalties, and shared economics.
- Co-development partnerprimary
Partners that fund and lead later-stage development and commercialization while Foghorn contributes discovery and early research.
- Future licensing counterpartiessecondary
Potential third parties that may license or collaborate on additional discovery programs if the platform produces attractive assets.
Foghorn is headquartered in Watertown, Massachusetts and operates as a U.S.-based biotech company with research and...
- •Headquartered in Watertown, Massachusetts, United States
- •Core research and development operations are U.S.-based
- •U.S. economics are shared with Lilly on key partnered programs
- •Ex-U.S. sales may generate tiered royalties on future products
- •No meaningful manufacturing footprint disclosed in the excerpts
Foghorn’s strategy is to convert its chromatin biology platform into partnered oncology medicines, using Lilly to fund...
01
Advance the SMARCA2-selective program with Lillyshort-term
This is the most visible clinical asset and a key proof point for the platform.
02
Expand the pipeline through additional discovery programsmedium-term
New programs diversify the platform and create future milestone and royalty opportunities.
03
Preserve economics through co-development and royaltiesmedium-term
Retaining U.S. profit share and ex-U.S. royalties improves long-term monetization without full commercialization burden.
Foghorn faces the typical risks of a clinical-stage biotech: no approved products, heavy reliance on R&D success, and...
Collaboration concentration with Lilly
A large share of future value is tied to one strategic partner and its development priorities.
- Scope
- U.S. economics, milestones, royalties
- Materiality
- high
Third-party manufacturing and CRO/CDMO disruption
The company relies on external contractors for research and clinical supply production.
- Scope
- Clinical trial materials and development timelines
- Materiality
- high
Competitive pressure in chromatin and protein degradation
Multiple biotech and pharma companies are pursuing similar targets and mechanisms.
- Scope
- SMARCA2 and related oncology targets
- Materiality
- medium
AI and machine learning governance risk
Use of AI tools can introduce data, IP, cybersecurity, and validation issues.
- Scope
- Protein structure prediction and discovery workflows
- Materiality
- medium
Revenue recognition for collaboration agreements
Can create lumpy quarterly revenue and affect comparability
Accrued research and development expenses
Can materially affect operating expenses and loss timing
R&D tax treatment and capitalization changes
Affects deferred tax balances and cash tax expectations
Coherus Oncology, Inc.
CHRS · Biological Products, (No Diagnostic Substances)
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
SOLIGENIX, INC.
SNGX · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Whitehawk Therapeutics, Inc.
WHWK · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
: 28.4.2026